Navigation Links
Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Date:5/14/2009

SEATTLE, May 14 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that Chief Executive Officer, Mitchell H. Gold, M.D., is a finalist for the Ernst & Young Entrepreneur Of The Year(R) 2009 Award in the Pacific Northwest. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mitchell Gold was selected as a finalist from nearly 65 nominations by a panel of independent judges. Award recipients will be announced at a special gala event on June 26, 2009 at the Seattle Sheraton.

"Dendreon is committed to improving the lives of cancer patients through the development of therapies that could someday offer safer and more effective treatment options to cancer patients in need, so I am thankful for this nomination. On behalf of all of our dedicated employees, we are honored to be recognized for these efforts to transform the way that cancer is treated," stated Dr. Gold.

The Ernst & Young Entrepreneur Of The Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

Regional award recipients are eligible for consideration for the Ernst & Young LLP Entrepreneur Of The Year national program. Award recipients in several national categories, as well as the overall national Ernst & Young Entrepreneur Of The Year award recipient, will be announced at the annual awards gala in Palm Springs, California on November 14, 2009. The awards are the culminating event of the Ernst & Young Strategic Growth Forum, the nation's most prestigious gathering of high-growth, market-leading companies.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepren
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... OLIGOMERIX, Inc. today announced the receipt of a ... $323,000 from the National Institute on Aging of the ... program is to develop novel biomarker assays for Alzheimer,s ... apolipoprotein E (apoE) proteins will be monitored in cerebrospinal ...
... FRANCISCO, Feb. 25 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic ... for the treatment of atherosclerosis. This patent is ...
... /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ), ... manufacturing and marketing biopharmaceutical products, today,announced that it ... and,full year ended December 31, 2008 after the ... Following the earnings announcement, ...
Cached Biology Technology:OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer's Disease 2VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 2VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 3VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 43SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... raise questions about why such losses matter and why ... traditionally responded to such questions by citing societal benefits ... like controlling pests and diseases, promoting the productivity of ... many others. Nevertheless, many of these presumed benefits are ...
... Battery technology hasn,t kept pace with advancements in portable ... One revolutionary concept being pursued by a team of ... capable of converting movement from humans or found in ... variable capacitor generators known as "dielectric elastomer generators" (DEGs) ...
... Rochelle, NY, April 6, 2011 The successful ... survival and reduce the risk of neurological consequences ... the premier issue of Therapeutic Hypothermia and ... published by Mary Ann Liebert, Inc. This groundbreaking ...
Cached Biology News:Precedent-setting evidence of the benefits of biodiversity 2Precedent-setting evidence of the benefits of biodiversity 3Precedent-setting evidence of the benefits of biodiversity 4Replacing batteries may become a thing of the past, thanks to 'soft generators' 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 3
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... Antibody Plate is a 96-well ELISA-compatible ... This antibody (mouse IgG 1 ) ... glutathione-S-transferase (GST), and binds with ... fusion protein in which the tag ...
... Testing Laboratory (RTL) can provide you ... years. ,,Microbial method development and validation ... the conditions of your GMP manufacturing ... products,,We offer a full spectrum of ...
... QED Bioscience has over 23 years of ... lines. We have made antibodies to large ... and viral antigens, and plasmid DNA-encoded antigens. ... is unique, so our hybridoma development programs ...
Biology Products: